Connect Biopharma Posts Q2 Results, Initiates IV Study Ahead of September Topline Data
CNTB sits 89% above its 52-week low of $1.23.
Summary
Connect Biopharma reported Q2 2026 results with $2.8M in license revenue from Simcere and $31.5M in cash, providing at least a one-year runway. R&D spending jumped to $16.3M from $8.8M a year ago, reflecting the Phase 2 Seabreeze STAT asthma and COPD studies. The company also initiated a Phase 2 IV study in August to bridge subcutaneous to IV dosing. Topline data from both Seabreeze STAT studies are expected in September 2026, a key inflection point that could support a Phase 3 program and FDA discussions.
At the time of this announcement, CNTB was trading at $2.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $146.7M. The 52-week trading range was $1.23 to $3.82. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.